Lyondennis6347

RESULTS Our in vivo results confirmed the predicted 1/b power law for PTE. Moreover, our analysis showed that using an axisymmetric b-tensor a power-law only exists under very specific conditions (a) "stick-like" tissue geometry and purely LTE or purely PTE waveforms; and (b) "pancake-like" tissue geometry and a purely LTE waveform. CONCLUSIONS A complete analysis of the power-law dependencies of the diffusion-weighted signal at high b-values has been performed. Only three specific forms of encoding result in a power-law dependency, pure linear and pure PTE when the tissue geometry is "stick-like" and pure LTE when the tissue geometry is "pancake-like". The different exponents of these encodings could be used to provide independent validation of the presence of different tissue geometries in vivo. © 2020 The Authors. Magnetic Resonance in Medicine published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine.OBJECTIVES The use of patient-reported outcome (PRO) measured outside clinical trials is not well defined. We report the first analysis of the prospective PRO study within the Swedish acute myeloid leukemia (AML) and the acute lymphoblastic leukemia (ALL) registries. METHODS PRO was requested 6 months after diagnosis. The EORTC Quality of life Questionnaire Core 30-item, the Patient Health Questionnaire-8 (PHQ-8), and questions from a Swedish National Cancer Questionnaire were used. RESULTS An invitation letter was sent to 398 patients; 255 (64%) responded, 60% web-based, and 40% on paper. The ALL cohort had lower physical, role and social functioning, higher symptom burden, and more financial difficulties compared to the AML cohort. A PHQ-8 score ≥ 10p, which indicates depression, was reported in 18% of the patients; 33% of these patients reported being prescribed antidepressants. The patients' overall experience of care was satisfying, but more psychological and practical support was desired. There was no difference in survival between patients who reported their PRO and those who did not. Follow-up at 2 and 4 years is ongoing. CONCLUSIONS PRO collected in a registry-based setting is feasible, but the selection of time points and questionnaires are delicate in a diverse patient population. © 2020 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.This paper discusses regression analysis of the failure time data arising from case-cohort periodic follow-up studies, and one feature of such data, which makes their analysis much more difficult, is that they are usually interval-censored rather than right-censored. Although some methods have been developed for general failure time data, there does not seem to exist an established procedure for the situation considered here. To address the problem, we present a semiparametric regularized procedure and develop a simple algorithm for the implementation of the proposed method. In addition, unlike some existing procedures for similar situations, the proposed procedure is shown to have the oracle property, and an extensive simulation is conducted and it suggests that the presented approach seems to work well for practical situations. The method is applied to an HIV vaccine trial that motivated this study. © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.Forkhead box M1 (FOXM1) and NF-ĸB are oncogenic drivers in liver cancer that positively regulate each other. We showed that methionine adenosyltransferase 1A (MAT1A) is a tumor suppressor in the liver and it inhibits NF-ĸB activity. Edralbrutinib Here we examined the interplay between FOXM1/NF-kB and MAT1A in liver cancer. We examined gene and protein expression, effects on promoter activities and binding of proteins to promoter regions, effects of FOXM1 inhibitors T0901317 (T0) and FDI-6 in vitro and in xenograft and syngeneic models of liver cancer. We found in both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) an induction in FOXM1 and NF-κB expression is accompanied by fall in MATα1 (protein encoded by MAT1A). The TCGA dataset confirmed the inverse correlation between FOXM1 and MAT1A. Interestingly, FOXM1 directly interact with MATα1 and they negatively regulate each other. In contrast, FOXM1 positively regulates p50 and p65 expression via MATα1, as the effect is lost in its absence. FOXM1, MATα1 and NF-κB all bind to the FOX-binding sites in the FOXM1 and MAT1A promoters. However, binding of FOXM1 and NF-κB repressed MAT1A promoter activity but activated FOXM1 promoter. In contrast, binding of MATα1 repressed FOXM1 promoter. MATα1 also binds and represses the NF-κB element in the presence of p65 or p50. Inhibiting FOXM1 with either T0 or FDI-6 inhibited liver cancer cell growth in vitro and in vivo. However, inhibiting FOXM1 had minimal effects in liver cancer cells that do not express MAT1A. CONCLUSION We have unveiled a novel crosstalk between FOXM1/NF-κB and MAT1A. Upregulation in FOXM1 lowers MAT1A but raises NF-κB expression and this is a feed forward loop that enhances tumorigenesis. This article is protected by copyright. All rights reserved.BACKGROUND The management of Crohn's disease patients with perianal lesions and anti-TNF failure is challenging. AIMS To assess the effectiveness of vedolizumab in perianal Crohn's disease and the predictors of success in a real-life cohort. METHODS We conducted a nationwide multicentre cohort study in patients with perianal Crohn's disease who received vedolizumab. In patients with active perianal Crohn's disease, the success of vedolizumab was defined by clinical success (no draining fistula at clinical examination and no anal ulcers for primary lesions) at 6 months without medical or surgical treatment for perianal Crohn's disease. Logistic regression analyses were performed to identify predictors of success. In patients with inactive perianal Crohn's disease, recurrence was defined by the occurrence of lesions and/or the need for medical or surgical treatments. RESULTS One hundred and fifty-one patients were included. Among them 102 patients had active perianal disease, 33 (32.4%) males, mean age 39.8 years, mean Crohn's disease duration 14.